The growing field of immuno-oncology is focused on exploiting the immune system's own defenses against tumors. Within these methods, inhibiting MAGEA3 with targeted antibodies holds considerable promise. MAGEA3, a part of the melanoma-associated antigen family, is often overexpressed in a range o